- Home
- ACIU vs EIC Comparison
ACIU vs EIC Comparison
Compare ACIU & EIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- EIC
- Stock Information
- Founded
- ACIU 2003
- EIC N/A
- Country
- ACIU Switzerland
- EIC United States
- Employees
- ACIU N/A
- EIC N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- EIC Finance/Investors Services
- Sector
- ACIU Health Care
- EIC Finance
- Exchange
- ACIU Nasdaq
- EIC Nasdaq
- Market Cap
- ACIU 247.4M
- EIC 287.1M
- IPO Year
- ACIU 2016
- EIC 2019
- Fundamental
- Price
- ACIU $1.88
- EIC $15.18
- Analyst Decision
- ACIU Strong Buy
- EIC Strong Buy
- Analyst Count
- ACIU 2
- EIC 1
- Target Price
- ACIU $12.00
- EIC $17.50
- AVG Volume (30 Days)
- ACIU 187.3K
- EIC 279.6K
- Earning Date
- ACIU 03-13-2025
- EIC 05-20-2025
- Dividend Yield
- ACIU N/A
- EIC 15.81%
- EPS Growth
- ACIU N/A
- EIC N/A
- EPS
- ACIU N/A
- EIC 1.97
- Revenue
- ACIU $30,136,397.00
- EIC $46,223,036.00
- Revenue This Year
- ACIU $120.91
- EIC $39.61
- Revenue Next Year
- ACIU $13.82
- EIC $27.28
- P/E Ratio
- ACIU N/A
- EIC $7.72
- Revenue Growth
- ACIU 84.51
- EIC 72.79
- 52 Week Low
- ACIU $1.77
- EIC $14.51
- 52 Week High
- ACIU $4.98
- EIC $16.71
- Technical
- Relative Strength Index (RSI)
- ACIU 29.21
- EIC 46.43
- Support Level
- ACIU $1.77
- EIC $14.70
- Resistance Level
- ACIU $2.05
- EIC $15.15
- Average True Range (ATR)
- ACIU 0.12
- EIC 0.24
- MACD
- ACIU -0.02
- EIC 0.02
- Stochastic Oscillator
- ACIU 18.71
- EIC 80.14
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About EIC Eagle Point Income Company Inc.
Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.